Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours

Kabasakal, Levent; Demirci, Emre; Ocak, Meltem; Decristoforo, Clemens; Araman, Ahmet; Özsoy, Yıldız; Uslu, İlhami; Kanmaz, Bedii

doi:10.1007/s00259-012-2123-y

Cited by 120 publications

(59 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Comparison of 68 Ga-DOTATOC and 68 Ga-DOTATATE (both sst 2 -specific tracers) in the same patient revealed comparable diagnostic accuracy for the detection of NET lesions (14). Another study compared the tumor detection rates between 68 Ga-DOTATATE PET (sst 2 -specific PET) and 68 Ga-DOTANOC PET (sst 2,3,5 -specific PET) in the same patient (15).…”

mentioning

confidence: 99%

Comparison of ⁶⁸Ga-DOTANOC and ⁶⁸Ga-DOTATATE PET/CT Within Patients with Gastroenteropancreatic Neuroendocrine Tumors

et al. 2013

View full text Add to dashboard Cite

Somatostatin receptor PET tracers such as [ 68 Ga-DOTA, 1-Nal 3 ]-octreotide ( 68 Ga-DOTANOC) and [ 68 Ga-DOTA,Tyr 3 ]-octreotate ( 68 Ga-DOTATATE) have shown promising results in patients with neuroendocrine tumors, with a higher lesion detection rate than is achieved with 18 F-fluorodihydroxyphenyl-Lalanine PET, somatostatin receptor SPECT, CT, or MR imaging. 68 Ga-DOTANOC has high affinity for somatostatin receptor subtypes 2, 3, and 5 (sst 2,3,5 ). It has a wider receptor binding profile than 68 Ga-DOTATATE, which is sst 2 -selective. The wider receptor binding profile might be advantageous for imaging because neuroendocrine tumors express different subtypes of somatostatin receptors. The goal of this study was to prospectively compare 68 Ga-DOTANOC and 68 Ga-DOTATATE PET/CT in the same patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and to evaluate the clinical impact of 68 Ga-DOTANOC PET/CT. Methods: Eighteen patients with biopsy-proven GEP-NETs were evaluated with 68 Ga-DOTANOC and 68 Ga-DOTATATE using a randomized crossover design. Labeling of DOTANOC and DOTATATE with 68 Ga was standardized using a fully automated synthesis device. PET/CT findings were compared with 3-phase CT scans and in some patients with MR imaging, 18 F-FDG PET/CT, and histology. Uptake in organs and tumor lesions was quantified and compared by calculation of maximum standardized uptake values (SUVmax) using volume computer-assisted reading. Results: Histology revealed low-grade GEP-NETs (G1) in 4 patients, intermediate grade (G2) in 7, and high grade (G3) in 7. 68 Ga-DOTANOC and 68 Ga-DOTATATE were false-negative in only 1 of 18 patients. In total, 248 lesions were confirmed by crosssectional and PET imaging. The lesion-based sensitivity of 68 Ga-DOTANOC PET was 93.5%, compared with 85.5% for 68 Ga-DOTATATE PET (P 5 0.005). The better performance of 68 Ga-DOTANOC PET is attributed mainly to the significantly higher detection rate of liver metastases rather than tumor differentiation grade. Multivariate analysis revealed significantly higher SUVmax in G1 tumors than in G3 tumors (P 5 0.009).This finding was less pronounced with 68 Ga-DOTANOC (P . 0.001). Altogether, 68 Ga-DOTANOC changed treatment in 3 of 18 patients (17%). Conclusion: The sst 2,3,5 -specific radiotracer 68 Ga-DOTANOC detected significantly more lesions than the sst 2 -specific radiotracer 68 Ga-DOTATATE in our patients with GEP-NETs. The clinical relevance of this finding has to be proven in larger studies.

show abstract

mentioning

confidence: 99%

Comparison of ⁶⁸Ga-DOTANOC and ⁶⁸Ga-DOTATATE PET/CT Within Patients with Gastroenteropancreatic Neuroendocrine Tumors

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Currently, 68 Ga-SMS-R-PET is regarded as the ideal nuclear medicine NET imaging tool and has, for all practical purposes, displaced OctreoScan®. Alternative PET techniques using 18 F-DOPA and 11 C-5HTP are effective, but have been supplanted by the increased availability and better performance of 68 Ga-SMS-R-PET [8,9].…”

Section: Integral Components Of the Techniquesmentioning

confidence: 99%

“…Thus, somatostatin receptor imaging (SRI), particularly with 68 Ga-SMS-R-PET, alters management in >50 % and successfully predicts response to cold or radiolabeled analogues [10,11]. Although conventional 18 fludeoxyglucose (FDG) PET is not a primary diagnostic tool in NETs, standardized uptake value (SUV) assessment can provide predictive information in terms of progression-free survival and response to peptide receptor radiotherapy (PRRT) [12,13].…”

Section: Strength Of Each Techniquementioning

confidence: 99%

“…Scintigraphy is classically carried out with Ga-SMS-R-PET), and the amine precursors 18 F-DOPA, and 11 C-5-hydroxytryptophan ( 11 C-5HTP) [3][4][5][6]. In nuclear medicine, radiolabeled somatostatin analogs (SSA) are the most utilized, since they represent an optimal paradigm of theranostics [7].…”

Section: Integral Components Of the Techniquesmentioning

confidence: 99%

“…use demonstrate a clear diagnostic superiority over the others [17,18]. 2) Preparation: Apart from DOTATOC, which has a European Pharmacopeia monograph, radiopharmaceuticals are prepared according to non-standardized local procedures.…”

Section: ) Preferred Peptide: None Of the Three Peptides Currently Inmentioning

confidence: 99%

See 2 more Smart Citations

The future of nuclear medicine imaging of neuroendocrine tumors: on a clear day one might see forever…

Bodei

Kidd

Prasad

et al. 2014

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Establishing Radiolanthanum Chemistry for Targeted Nuclear Medicine Applications

Aluicio‐Sarduy

Thiele

Martin

et al. 2020

Chemistry A European J

View full text Add to dashboard Cite

We report the first targeted nuclear medicine application of the lanthanum radionuclides 132/135La. These isotopes represent a matched pair for diagnosis via the positron emissions of 132La and therapy mediated by the Auger electron emissions of 135La. We identify two effective chelators, known as DO3Apic and macropa, for these radionuclides. The 18‐membered macrocycle, macropa, bound 132/135La with better molar activity than DO3Apic under similar conditions. These chelators were conjugated to the prostate‐specific membrane antigen (PSMA)‐targeting agent DUPA to assess the use of radiolanthanum for in vivo imaging. The 132/135La‐labeled targeted constructs showed high uptake in tumor xenografts expressing PSMA. This study validates the use of these radioactive lanthanum isotopes for imaging applications and motivates future work to assess the therapeutic effects of the Auger electron emissions of 135La.

show abstract

Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours

Abstract: Our study demonstrated that the images obtained by (68)Ga-DOTATATE and (68)Ga-DOTANOC have comparable diagnostic accuracy. However, (68)Ga-DOTATATE seems to have a higher lesion uptake and may have a potential advantage.

Cited by 120 publications

References 23 publications

Comparison of ⁶⁸Ga-DOTANOC and ⁶⁸Ga-DOTATATE PET/CT Within Patients with Gastroenteropancreatic Neuroendocrine Tumors

Comparison of ⁶⁸Ga-DOTANOC and ⁶⁸Ga-DOTATATE PET/CT Within Patients with Gastroenteropancreatic Neuroendocrine Tumors

The future of nuclear medicine imaging of neuroendocrine tumors: on a clear day one might see forever…

Establishing Radiolanthanum Chemistry for Targeted Nuclear Medicine Applications

Contact Info

Product

Resources

About

Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours

Abstract: Our study demonstrated that the images obtained by (68)Ga-DOTATATE and (68)Ga-DOTANOC have comparable diagnostic accuracy. However, (68)Ga-DOTATATE seems to have a higher lesion uptake and may have a potential advantage.

Cited by 120 publications

References 23 publications

Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT Within Patients with Gastroenteropancreatic Neuroendocrine Tumors

Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT Within Patients with Gastroenteropancreatic Neuroendocrine Tumors

The future of nuclear medicine imaging of neuroendocrine tumors: on a clear day one might see forever…

Establishing Radiolanthanum Chemistry for Targeted Nuclear Medicine Applications

Contact Info

Product

Resources

About

Comparison of ⁶⁸Ga-DOTANOC and ⁶⁸Ga-DOTATATE PET/CT Within Patients with Gastroenteropancreatic Neuroendocrine Tumors

Comparison of ⁶⁸Ga-DOTANOC and ⁶⁸Ga-DOTATATE PET/CT Within Patients with Gastroenteropancreatic Neuroendocrine Tumors